R. Espinosa-Romero

Epidemiological overview, advances in diagnosis, prevention, treatment and management of epithelial ovarian cancer in Mexico.

L. Oñate-Ocaña, D. Gallardo-Rincón, A. Meneses-García, 2016, Salud publica de Mexico.

Clinical Evaluation of BRCA1/2 Mutation in Mexican Ovarian Cancer Patients

D. Gallardo-Rincón, Elizabeth Hernández-Nava, Alfredo Toledo-Leyva, 2019, Translational oncology.

High prevalence of human papillomavirus and European variants of HPV 16 infecting concomitantly to cervix and oral cavity in HIV positive women

A. García-Carrancá, Carlos Pérez-Plascencia, D. Cantú de León, 2020, PloS one.

Clinical Benefits of Olaparib in Mexican Ovarian Cancer Patients With Founder Mutation BRCA1-Del ex9-12

D. Gallardo-Rincón, Abraham Pedroza-Torres, L. Cetina-Pérez, 2022, Frontiers in Genetics.

Standard Treatment with Bevacizumab as Targeted Therapy in Cervical Cancer.

L. Cetina-Pérez, P. Cortês-Esteban, J. Coronel-Martínez, 2020, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

Experience with the use of olaparib in patients with ovarian cancer

D. Gallardo-Rincón, Alfredo Toledo-Leyva, D. Isla-Ortiz, 2020, Gaceta de M�xico.